Scott Barros

Q Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index6.3kcitations33works2.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Interference and Gene Delivery(17), Advanced biosensing and bioanalysis techniques(14), MicroRNA in disease regulation(10), DNA and Nucleic Acid Chemistry(4), Drug Transport and Resistance Mechanisms(4)

Publications33 total

In Vivo generation of anti-CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases
Blood·2025· 2 cited
<i>In Vivo</i> panCAR-Mediated Depletion of B Cells in Non-Human Primates Using a Circular (oRNA®) Anti-CD20 CAR
Blood·2024· 3 cited
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Nature Nanotechnology·2019· 1.5k citedOpen Access
Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
Nucleic Acids Research·2019· 77 citedOpen Access
Genotoxicity Tests for Novel Oligonucleotide‐Based Therapeutics
2018· 1 cited
Impact of Oligonucleotide Structure, Chemistry, and Delivery Method on <i>In Vitro</i> Cytotoxicity
Nucleic Acid Therapeutics·2016· 42 cited
Exposure to siRNA-GalNAc Conjugates in Systems of the Standard Test Battery for Genotoxicity
Nucleic Acid Therapeutics·2016· 26 cited
Discovery and Development Strategies for Small Interfering RNAs
2016· 2 cited
OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics
Nucleic Acid Therapeutics·2016· 43 cited
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
Nature Medicine·2015· 290 cited
279 Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated With Alpha-1-Antitrypsin Deficiency
Gastroenterology·2015· 10 cited
A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B
Blood·2014· 15 cited
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Nature Communications·2014· 604 citedOpen Access
850c RNAi Therapeutics Ameliorate Liver Disease Associated with Alpha-1-Antitrypsin Deficiency
Gastroenterology·2014
Correction for Ehre et al., Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs
Proceedings of the National Academy of Sciences·2014· 1 citedOpen Access
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Proceedings of the National Academy of Sciences·2014· 471 citedOpen Access
Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy
Molecular Therapy — Nucleic Acids·2014· 212 citedOpen Access
Abstract 15574: A Subcutaneous Platform for RNAi Therapeutics Targeting ANGPTL3
Circulation·2013· 1 cited
Expanded Therapeutic Index Of Antithrombin Silencing and Correction Of Aptt In a Hemophilia A Mouse Model
Blood·2013· 2 cited
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Molecular Therapy·2013· 594 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Akin Akinc(13), Muthiah Manoharan(9), June Qin(7), Martin A. Maier(7), Kevin Fitzgerald(7), Julia Hettinger(7), Klaus Charissé(7), Alfica Sehgal(7), Yongfeng Jiang(6), Kallanthottathil G. Rajeev(5), Muthusamy Jayaraman(5), Renta Hutabarat(5), Mary Carioto(5), Pieter R. Cullis(4), Tatiana I. Novobrantseva(4), William Querbes(4), Varun Kumar(4), Stuart Milstein(4), Satya Kuchimanchi(4), Amy Simon(4)